🇺🇸 FDA
Patent

US 11472889

Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof

granted A61KA61K2039/505A61P

Quick answer

US patent 11472889 (Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof) held by CytomX Therapeutics, Inc. expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CytomX Therapeutics, Inc.
Grant date
Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2039/505, A61P, A61P35/00